AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMMUTEP LTD

0.270

0.000

Volume:1.03M

Turnover:279.29K

Market Cap:394.31M

PE:-8.21

High:0.275

Open:0.275

Low:0.265

Close:0.270

Loading ...

Overview Company News Filings

Immutep Ltd. Unveils Corporate Presentation Highlighting Advances in LAG-3 Immunotherapy for Cancer and Autoimmune Diseases

BRIEF-Immutep’S Efti With Radiotherapy & KEYTRUDA® Meets Primary Endpoint In Phase 2 For Soft Tissue Sarcoma

Immutep’s Efti With Radiotherapy & Keytruda® (Pembrolizumab) Meets Primary Endpoint in Phase Ii for Soft Tissue Sarcoma

THOMSON REUTERS

Immutep Combination Therapy Increases Tumor Fibrosis Rate in Soft Tissue Sarcoma Trial

MT Newswires Live

Immutep Ltd. Secures Polish Government Grant for EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

Immutep ADRs Rise on Trial Results for Non-Small Cell Lung Cancer Treatment

Immutep’s Efti With Keytruda® (Pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

THOMSON REUTERS

Guess which ASX 300 stock is jumping 11% on big news

Immutep Reports Nearly 61% Response Rate, 90% Disease Control Rate in Non-Squamous Non-Small Cell Lung Cancer Trial

MT Newswires Live

Immutep Cancer Treatment Shows High Survival Rate

Immutep’s Efti in Combination With Keytruda® (Pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer With CPS <1

THOMSON REUTERS

Immutep Ltd - No New Safety Signals for Eftilagimod Alfa With Pembrolizumab

THOMSON REUTERS

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1

Immutep Says Overall Survival of 17.6 Months Achieved in Head, Neck Squamous Cell Cancer Trial

MT Newswires Live

Immutep Quarterly Activities Report Q3 FY25

Immutep Posts AU$92.5 Million Cash Balance in March Quarter

MT Newswires Live

Immutep to Participate in Upcoming Investor Conferences

First Patient Dosed in Immutep’s Tacti-004 Phase Iii Trial in First Line Non-Small Cell Lung Cancer

THOMSON REUTERS

Immutep notches upward on first lung cancer patient dosing

The Market Herald

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/IMM.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.27,"timestamp":1749190320000,"preClose":0.27,"halted":0,"volume":1031469,"delay":0,"nameEN":"IMMUTEP LTD","floatShares":1236885566,"shares":1460389575,"eps":-0.032898,"marketStatus":"Market Closed","change":0,"latestTime":"06-06 16:12:00 AEST","open":0.275,"high":0.275,"low":0.265,"amount":279294,"amplitude":0.037037,"askPrice":0.275,"askSize":62000,"bidPrice":0.265,"bidSize":36361,"shortable":3,"etf":0,"ttmEps":-0.032898,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1749513600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.27,"openAndCloseTimeList":[[1749168000000,1749189600000]],"volumeRatio":0.7568620430687609,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1236885566,"roa":"-20.35%","roe":"-30.45%","lyrEps":-0.035565,"volumeRatio":0.7568620430687609,"shares":1460389575,"dividePrice":0,"high":0.275,"amplitude":0.037037,"preClose":0.27,"low":0.265,"week52Low":0.222,"pbRate":"2.29","psRate":"80.82","week52High":0.44,"institutionHeld":0,"latestPrice":0.27,"committee":-0.260662,"eps":-0.032898,"divideRate":0,"volume":1031469,"delay":0,"ttmEps":-0.032898,"open":0.275,"prevYearClose":0.365,"prevWeekClose":0.285,"prevMonthClose":0.285,"prevQuarterClose":0.28,"fiveDayClose":0.285,"twentyDayClose":0.295,"sixtyDayClose":0.275},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540587417","title":"Immutep Ltd. Unveils Corporate Presentation Highlighting Advances in LAG-3 Immunotherapy for Cancer and Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2540587417","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540587417?lang=en_us&edition=fundamental","pubTime":"2025-06-02 07:17","pubTimestamp":1748819855,"startTime":"0","endTime":"0","summary":"Immutep Ltd. has released a corporate presentation highlighting its leadership in LAG-3 immunotherapy. The company is focusing on four clinical-stage assets and a preclinical program aimed at combating cancer and autoimmune diseases. The presentation details their first-in-class lead clinical candidates, including Efti, a novel MHC II agonist showing strong efficacy and a favorable safety profile in multiple cancers. Additionally, Immutep is conducting a Phase III trial in collaboration with MSD, evaluating Efti in combination with KEYTRUDA and chemotherapy for first-line treatment of non-small cell lung cancer. Immutep maintains full commercial rights to Efti. The company has multiple collaborations with large pharma and leading institutions. Immutep reports a strong intellectual property portfolio and a solid financial position with cash and cash equivalents of approximately A$146.25 million as of March 2025. You can access the full presentation through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nNDL5svFFr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2538469544","title":"BRIEF-Immutep’S Efti With Radiotherapy & KEYTRUDA® Meets Primary Endpoint In Phase 2 For Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2538469544","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538469544?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:44","pubTimestamp":1748349870,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep’S Efti With Radiotherapy & KEYTRUDA Meets Primary Endpoint In Phase 2 For Soft Tissue SarcomaMay 27 (Reuters) - Immutep Ltd IMM.AX:IMMUTEP’S EFTI WITH RADIOTHERAPY & KEYTRUDA (PEMBROLIZU","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUALJCMH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2538465765","title":"Immutep’s Efti With Radiotherapy & Keytruda® (Pembrolizumab) Meets Primary Endpoint in Phase Ii for Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2538465765","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538465765?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:00","pubTimestamp":1748347203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUALJCMH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2538314447","title":"Immutep Combination Therapy Increases Tumor Fibrosis Rate in Soft Tissue Sarcoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2538314447","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538314447?lang=en_us&edition=fundamental","pubTime":"2025-05-26 09:06","pubTimestamp":1748221581,"startTime":"0","endTime":"0","summary":"Immutep  said its Phase II EFTISARC-NEO trial evaluating the therapy of the company's drug candidate eftilagimod alfa, in combination with prescription medicine Keytruda and radiotherapy as treatment for patients with resectable soft tissue sarcoma , showed an increase in tumor fibrosis rate, according to a Monday filing with the Australian bourse.The trial showed that the combination therapy exceeded the median tumor fibrosis rate of 35% compared to the historical median of 15% observed with radiotherapy alone, meeting the trial's primary endpoint, the filing said.Tumor fibrosis is linked to improved overall and recurrence-free survival in patients with STS.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2538444131","title":"Immutep Ltd. Secures Polish Government Grant for EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2538444131","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538444131?lang=en_us&edition=fundamental","pubTime":"2025-05-26 09:05","pubTimestamp":1748221552,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on May 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250526:nNDL5vlndY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2538714750","title":"Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2538714750","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538714750?lang=en_us&edition=fundamental","pubTime":"2025-05-26 08:43","pubTimestamp":1748220200,"startTime":"0","endTime":"0","summary":"Commenting on the clinical trial results helping boost the ASX 300 healthcare stock today, medical oncologists Katarzyna Kozak and Pawe Sobczuk at MSCNRIO, said:  It is very encouraging to see the chemotherapy-free combination with efti far exceed the ambitious target we initially set for the trial's primary endpoint in resectable soft tissue sarcoma. These results support our belief that efti's activation of antigen-presenting cells, and in turn a broad adaptive and innate immune response, helps transform the immunosuppressed tumour microenvironment of soft tissue sarcomas leading to strong anti-cancer efficacy.  The oncologists added, \"There remains a very high unmet need in this aggressive orphan cancer indication, and we look forward to presenting detailed results at a medical meeting later this year.\" Immutep share price snapshot Despite the big lift since April's one-year lows, with today's intraday boost factored in, shares in the ASX 300 healthcare stock remain down 33% since t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/26/up-34-since-april-asx-300-healthcare-stock-lifts-off-again-today-on-new-milestone/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK7508","IMM.AU","XKO.AU"],"gpt_icon":0},{"id":"2535820005","title":"Immutep ADRs Rise on Trial Results for Non-Small Cell Lung Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2535820005","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535820005?lang=en_us&edition=fundamental","pubTime":"2025-05-15 23:36","pubTimestamp":1747323360,"startTime":"0","endTime":"0","summary":"American depository receipts of Immutep rose after the company reported positive results from a trial of its combination treatment for non-small cell lung cancer.Immutep climbed 16% to $2.11 on Thursday. The ADRs have declined 25% over the past 12 months.The late-stage immunotherapy company said Thursday the combination of  its Efti with Merck's Keytruda showed a 60.8% response rate for patients with advanced or metastatic non-squamous non-small cell lung cancer, compared to a historical control of 48%.The combination also demonstrated a 90.2% disease control rate, the company said.The combination involves eftilagimod alpha in combination with anti-PD-1 therapy Keytruda and doublet chemotherapy as first-line treatment.Chief Executive Marc Voigt said the company's confidence in its efti treatment continues to rise with the latest trial data. Immutep now has data from 165 patients treated with the combination, with or without chemotherapy.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0070302665.USD","LU0238689110.USD","LU0122379950.USD","IE00BLSP4452.SGD","BK4559","IE00BJT1NW94.SGD","LU1989772923.USD","LU0965509101.SGD","IE00B4R5TH58.HKD","IE00BSNM7G36.USD","LU1989772840.SGD","IMMP","LU1066051225.USD","LU1989771016.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0965508806.USD","LU1585245621.USD","LU0265550359.USD","SGXZ57979304.SGD","LU0320765646.SGD","LU2361044865.SGD","BK7067","LU0234572021.USD","SG9999002232.USD","BK4550","LU0965509283.SGD","LU1929549753.HKD","BK7508","LU1035773651.USD","LU1057294990.SGD","LU1093756325.SGD","LU0320765489.SGD","LU1061106388.HKD","LU1066053197.SGD","LU2361045086.USD","IMM.AU","BK4533","LU2023250843.SGD","SG9999014575.USD","SG9999001176.SGD","LU0006306889.USD","SG9999015358.SGD","IE00BN8TJ469.HKD","SG9999015341.SGD","IE00BBT3K403.USD","LU1069347547.HKD","LU1066051811.HKD"],"gpt_icon":1},{"id":"2535441978","title":"Immutep’s Efti With Keytruda® (Pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2535441978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535441978?lang=en_us&edition=fundamental","pubTime":"2025-05-15 20:00","pubTimestamp":1747310404,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nTUABYTNHL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2535835769","title":"Guess which ASX 300 stock is jumping 11% on big news","url":"https://stock-news.laohu8.com/highlight/detail?id=2535835769","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535835769?lang=en_us&edition=fundamental","pubTime":"2025-05-15 09:11","pubTimestamp":1747271519,"startTime":"0","endTime":"0","summary":"Immutep Ltd  shares are catching the eye on Thursday. In morning trade, the ASX 300 stock is up 11% to 31 cents. Why is this ASX 300 stock rocketing?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/15/guess-which-asx-300-stock-is-jumping-11-on-big-news-2/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["INAQU","IMM.AU","BK7067","BK7508","TPS.AU"],"gpt_icon":0},{"id":"2535880158","title":"Immutep Reports Nearly 61% Response Rate, 90% Disease Control Rate in Non-Squamous Non-Small Cell Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2535880158","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535880158?lang=en_us&edition=fundamental","pubTime":"2025-05-15 08:21","pubTimestamp":1747268472,"startTime":"0","endTime":"0","summary":"Immutep  reported a 60.8% response rate and 90.2% disease control rate in the Insight-003 trial, according to a Thursday filing with the Australian bourse.The trial is evaluating eftilagimod alpha in combination with anti-PD-1 therapy, Keytruda, and doublet chemotherapy as first-line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer, the filing said.The overall response rate in all evaluable patients showed a \"significant\" improvement compared with historical control from a registrational trial of anti-PD-1 and doublet chemotherapy in non-squamous non-small cell lung cancer, according to the filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2533983584","title":"Immutep Cancer Treatment Shows High Survival Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533983584","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533983584?lang=en_us&edition=fundamental","pubTime":"2025-05-05 21:05","pubTimestamp":1746450300,"startTime":"0","endTime":"0","summary":"Immutep said a treatment it is developing showed strong results in overall survival among head and neck cancer patients.The Australian cancer-treatment company said Monday the median rate for overall survival was 17.6 months for patients taking a combination of eftilagimod alfa and Merck's pembrolizumab drug Keytruda.Shares rose 8% to $1.85 in premarket trading Monday.The drug combination is designed to treat people with recurrent or metastatic head and neck squamous cell carcinoma. Combining the therapies has increased response rates by sevenfold and more than doubled median overall survival compared with historical results. The treatment has no new safety signals, Immutep said.Immutep has requested a meeting with the Food and Drug Administration to discuss next steps including paths to approval. The company is continuing patient follow-ups, data collection and analysis, and plans to provide a further update later this year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Immutep Cancer Treatment Shows High Survival Rate","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0861579265.USD","LU2106854487.HKD","SG9999001176.SGD","MRK","BK4550","IE00BN8TJ469.HKD","LU0058720904.USD","LU0965509010.AUD","LU1291159041.SGD","LU2324357040.USD","LU0122379950.USD","LU0965509283.SGD","LU1934455194.USD","IE00BJJMRZ35.SGD","LU1699723380.USD","SG9999014567.USD","IE00BFTCPJ56.SGD","LU1023059063.AUD","LU1989772923.USD","LU1035773651.USD","LU1974910355.USD","LU2461242641.AUD","LU1430594728.SGD","LU0234572021.USD","LU1066051225.USD","IMMP","LU1162221912.USD","BK7067","LU0289739699.SGD","SGXZ57979304.SGD","IE00B2B36J28.USD","LU1037948897.HKD","LU0985320562.USD","LU1941712348.USD","BK4585","LU1941712264.USD","LU1934455277.USD","LU2468319806.SGD","BK4534","LU0106261372.USD","IMM.AU","LU2361044949.HKD","LU1057294990.SGD","LU0211331839.USD","BK4139","LU1989772840.SGD","SG9999002224.SGD","BK4516","LU0238689110.USD","LU1585245621.USD"],"gpt_icon":0},{"id":"2533854586","title":"Immutep’s Efti in Combination With Keytruda® (Pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer With CPS <1","url":"https://stock-news.laohu8.com/highlight/detail?id=2533854586","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533854586?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:01","pubTimestamp":1746446490,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nFWN3RD20G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2533586830","title":"Immutep Ltd - No New Safety Signals for Eftilagimod Alfa With Pembrolizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586830","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586830?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:01","pubTimestamp":1746446490,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nFWN3RD20G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2533458652","title":"Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1","url":"https://stock-news.laohu8.com/highlight/detail?id=2533458652","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533458652?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446400,"startTime":"0","endTime":"0","summary":"Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1. Mature overall survival data builds on encouraging high response rates with multiple complete responses. Patients with CPS <1 represent a high unmet medical need and have no available treatment options without chemotherapy. Meeting with FDA has now been requested to discuss next steps including potential paths to approval. Patients with CPS <1 in 1L HNSCC represent a treatment population with high unmet medical need. Up to 20% of 1L HNSCC patients have CPS <1 and despite immunotherapy’s progress in fighting cancer, anti-PD-1 therapy alone  is only approved for patients who express PD-L1 . Additionally, all available treatment options for patients with PD-L1 CPS <1 include chemotherapy.Importantly, efti in combination with pembrolizumab continues to be well-tolerated with no new safety signals. This safety and mature OS data build on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-efti-combination-keytruda-pembrolizumab-120000632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["APC","LU0234572021.USD","IMMP","LU2106854487.HKD","LU1291159041.SGD","LU1093756325.SGD","LU0265550359.USD","BK4534","BK4007","LU0058720904.USD","BK7508","LU1057294990.SGD","LU0861579265.USD","LU1941712264.USD","BK7095","IE0009355771.USD","LU0985320562.USD","LU0106261372.USD","OS","IMM.AU","LU1066051498.USD","LU1066053197.SGD","SG9999001176.SGD","LU2417539215.USD","BK4533","CPS","IE000M9KFDE8.USD","LU0070302665.USD","LU2361044865.SGD","IE00BLSP4239.USD","LU0965509283.SGD","LU2237443382.USD","LU2461242641.AUD","IE00B4R5TH58.HKD","LU0211331839.USD","IE00BN8TJ469.HKD","LU1983299246.USD","LU1496350171.SGD","MRK","APC.AU","IE00BFTCPJ56.SGD","LU2112291526.USD","IE00BSNM7G36.USD","IE00BLSP4452.SGD","LU1934455194.USD","BK4139","SG9999014559.SGD","LU1069347547.HKD","LU0265550946.USD","SG9999001176.USD"],"gpt_icon":0},{"id":"2533212403","title":"Immutep Says Overall Survival of 17.6 Months Achieved in Head, Neck Squamous Cell Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2533212403","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533212403?lang=en_us&edition=fundamental","pubTime":"2025-05-05 08:18","pubTimestamp":1746404337,"startTime":"0","endTime":"0","summary":"Immutep (ASX:IMM) said that a median overall survival of 17.6 months was achieved in cohort B of the TACTI-003 phase IIb trial, which is evaluating its eftilagimod alfa drug candidate in combination w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2531078031","title":"Immutep Quarterly Activities Report Q3 FY25","url":"https://stock-news.laohu8.com/highlight/detail?id=2531078031","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531078031?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:00","pubTimestamp":1745928000,"startTime":"0","endTime":"0","summary":"First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestone. Pivotal TACTI-004 trial design presented at the European Lung Cancer Congress  2025. Patient enrolment completed for the INSIGHT-003 Phase I trial evaluating efti with KEYTRUDA and chemotherapy as first-line treatment of advanced or metastatic 1L NSCLC. Immutep also presented the pivotal TACTI-004 Phase III trial as a Trial-in-Progress poster at the European Lung Cancer Congress  2025, in Paris, France, in late March. The poster included an overview and study design of the TACTI-004 Phase III trial. Informed by the Company’s AIPAC-003 study, Immutep has determined to move forward with 30 mg efti dosing as the optimal biological dose. We have observed encouraging support from the investigators participating in the study in our meetings to date including those held at ELCC 2025 and after quarter end at the investigator meeting in Budapest, Hungary. Consistent feedback has been that the e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-quarterly-activities-report-q3-120000588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","LU1057294990.SGD","IE00BLSP4239.USD","LU2468319806.SGD","IE0002141913.USD","LU1941712264.USD","SG9999001440.SGD","SGXZ57979304.SGD","LU1989772840.SGD","LU0106261372.USD","LU0058720904.USD","LU1035773651.USD","LU0238689110.USD","CTOS","IE00B1BXHZ80.USD","LU1116320901.HKD","LU1941712348.USD","LU0203345920.USD","SG9999015341.SGD","BK4533","MRK","BK4588","BK4007","INAQU","LU0122379950.USD","LU0208291251.USD","SG9999015358.SGD","LU0203347892.USD","LU2361044949.HKD","LU2023250843.SGD","IMM.AU","IMMP","LU2361045086.USD","IE00B4R5TH58.HKD","LU1037948897.HKD","LU1585245621.USD","LU0320765489.SGD","LU1934455194.USD","SG9999014542.SGD","LU1061106388.HKD","LU1917777945.USD","LU1699723380.USD","LU1037948541.HKD","LU1430594728.SGD","LU1989771016.USD","SG9999001176.USD","IE00BJJMRZ35.SGD","LU2461242641.AUD","LU1066051811.HKD","LU1093756168.USD","IE00BBT3K403.USD"],"gpt_icon":0},{"id":"2531921273","title":"Immutep Posts AU$92.5 Million Cash Balance in March Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2531921273","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531921273?lang=en_us&edition=fundamental","pubTime":"2025-04-29 10:37","pubTimestamp":1745894241,"startTime":"0","endTime":"0","summary":"Immutep  ended the fiscal third quarter with a cash balance of AU$92.5 million, according to a Tuesday filing with the Australian bourse.It also has short-term bank deposits of AU$53.8 million, the filing said.The clinical-stage biotechnology company saw progress in its ongoing trials during the quarter. This year, it expects analysis and safety assessment reports for treatments of breast cancer and autoimmune disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2524467908","title":"Immutep to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2524467908","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524467908?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:00","pubTimestamp":1743595200,"startTime":"0","endTime":"0","summary":"SYDNEY, AUSTRALIA , April 02, 2025  -- Immutep Limited  , a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:. Additional information for the Jefferies presentationwill be made available closer to the conference on theEvents pagewithin the Investors & Media section of Immutep’s website.About ImmutepImmutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 , and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.U.S. Media:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-participate-upcoming-investor-conferences-120000160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["IMMP","BK4139","IMM.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2522223070","title":"First Patient Dosed in Immutep’s Tacti-004 Phase Iii Trial in First Line Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522223070","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522223070?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:00","pubTimestamp":1742904003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUA13BLV1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2522105855","title":"Immutep notches upward on first lung cancer patient dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522105855","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522105855?lang=en_us&edition=fundamental","pubTime":"2025-03-25 08:17","pubTimestamp":1742861820,"startTime":"0","endTime":"0","summary":"Immutep Ltd  has dosed the first patient of its Phase 3 TACTI-004 non-small cell lung cancer trial – the final stage of clinical study before the company eventually takes final efficacy results to regulators.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.That’ll eventually include the FDA, given Immutep’s dual Australia-U.S. share listing, where the company sits on the NASDAQ.But first, the company needs to prove to Australia’s TGA its drugs are effective.“Trial results will inform potential marketing approval application in non-small cell lung cancer, one of the largest indications in oncology,” the company said.Non-small cell lung cancer  is the most common type of lung cancer affecting the tissues of the organs themselves. Ultimately, all three dominant types of NSCLC are carcinomas.The material provided in this article is for information only and should not be treated as invest","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/immutep-notches-upward-on-first-lung-cancer-patient-dosing-2025-03-25/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":50,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[]}}